Managing the Veterinary Cancer Patient: A Practice Manual

By Gregory K. Ogilvie and Antony S. Moore

Book Overview

Book by Ogilvie, Gregory K. This description may be from another edition of this product.

• Format: Paperback
• Language: English
• ISBN: 1884254209
• ISBN13: 9781884254208
• Release Date: January 1995
• Publisher: Veterinary Learning Systems
• Weight: 2.35 lbs.
• Dimensions: 9.5" x 1.0" x 7.0"

Customer Reviews

An Excellent and Readable Textbook

Speaking as a board-certified veterinary oncologist, this is one of the most useful textbooks that I own. It is a practical handbook for students, general veterinary practitioners and clients but it is also provides enough detail to be useful to specialists. The chapters on specific diseases represent the most thorough review of the veterinary oncology literature that has been conducted in many years, perhaps ever. The book discusses controversial points in detail rather than making blanket conclusions, and the source of the information is always identified - usually the scientific literature (carefully referenced) and occasionally the considerable professional experience of the authors (noted when this is the case). In comparison to the other major veterinary oncology textbooks on the market it is by far the standout for its precision and thoroughness, and for the thoughtful presentation that makes this wealth of information accessible and digestible. Bravo to the authors for their contribution to the field.

Overall good textbook

Managing the Veterinary Cancer Patient is a good, basic oncology textbook for the veterinary practitioner. Understandably, people have concerns about the dose of CCNU. It should be noted however (contrary to what was stated in another review) that 60-90mg/m2 doses given repeatedly are not fatal in 100% of patients. Two scientific articles published within the last year (JVIM) demonstrate that some dogs can tolerate dosages in the 60-90mg/m2 range. Admittedly, the potential for irreversible thrombocytopenia should force us to act cautiously (and perhaps more conservatively) when using CCNU. However, we should also refrain from branding those that recommend higher doses of CCNU as "irresponsible" and from implying that they should be deemed liable for any unfortunate outcomes.